(Q33848334)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

1 reference

title

Insulin analogs and glycosylated hemoglobin target of less than 7% in type 2 diabetes: a systematic review of randomized trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

1 reference

1 reference

glycosylated hemoglobin

23 October 2023

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Paolo Chiodini

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Dario Giugliano

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1

Katherine Esposito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Giuseppe Bellastella

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

16 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

Metabolic syndrome and related disorders

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

167-176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

25 January 2020

cites work

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study).

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Measuring progress toward achieving hemoglobin A1c goals in diabetes care: pass/fail or partial credit

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Quantifying heterogeneity in a meta-analysis

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Meta-analysis in clinical trials

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Reporting bias in medical research - a narrative review

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

The market in diabetes

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/references/10.1089/MET.2010.0134

Identifiers

DOI

10.1089/MET.2010.0134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21410335%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference